Analyst consensus rating
Avita Medical Analyst Rating: Strong Buy
RCEL is rated Strong Buy by 3 analysts with a $11.15 target. As of 2026-08-21.
Direct answer
Avita Medical's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.15.
Forecast evidence checked August 21, 2026.
Get free Avita Medical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.06
- Average price target
- $11.15
- High price target
- $14.16
- Low price target
- $8.16
- Low target gap
- -18.9%
- Target upside
- +10.8%
- High target gap
- +40.7%
- Target range width
- 59.6%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Avita Medical?
Avita Medical has a verified Strong Buy consensus. The same dataset has an average price target of $11.15.
How far are Avita Medical's low and high targets from the recorded price?
The low target implies -18.9%, while the high target implies +40.7%.
How many analysts are included in Avita Medical's consensus?
The verified consensus includes 3 analysts.
How is Avita Medical's target upside or downside calculated?
The average target of $11.15 is divided by the recorded price of $10.06, then one is subtracted to produce +10.8%. This does not guarantee a future return.
When was Avita Medical's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.